How do GLP-1 receptor agonists and metformin affect glaucoma risk in patients with Type 2 diabetes? Join Dr. Ike Ahmed and Jawad Muayad as they discuss the data on diabetes treatments and glaucoma risk with Dr. Emily Schehlein. From their Ophthalmology article, “Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes.”

Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes. Muayad, Jawad et al. Ophthalmology. In press.